Strongbridge Biopharma
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Show More
CEO
Matthew Pauls
Employees
72
Country
United States
ISIN
IE00BYZ5XL97
Listings
0 Comments
Share your thoughts
FAQs
What is Strongbridge Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Strongbridge Biopharma stocks are traded under the ticker 69BN.STU.
How many employees does Strongbridge Biopharma have?▼
As of November 2, 2026, the company has 72 employees.
In which sector is Strongbridge Biopharma located?▼
Strongbridge Biopharma operates in the Manufacturing sector.
When did Strongbridge Biopharma complete a stock split?▼
Strongbridge Biopharma has not had any recent stock splits.
Where is Strongbridge Biopharma headquartered?▼
Strongbridge Biopharma is headquartered in Trevose, United States.